Fat but Fit: Fact or Myth?

EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.

EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.

FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.

Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.

A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.

Semaglutide brought 40.4% of children below the obesity BMI threshold, according to top-line results from the phase 3 STEP Young clinical trial.

US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.

A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.